Put Merck to work? [Video]

Giles Coghlan LLB, Lth, MA Financial Source

Merck & Co is a multinational healthcare US company which is based in New Jersey. Originally founded in Germany Merck is known for its development of medicines, vaccines, and biological therapies. With Goldman Sachs raising its probability of the US economy entering a recession in the next 12 months by 10bps to 35% is it worth looking at Merck’s strong seasonals? Although the healthcare sector is not ‘recession proof’ the healthcare sector has a reputation for performing well during economic downturns.

The seasonals are certainly strong. Over the last 10 years between March 17 and June 9, Merck’s shares have risen by an average of over 6%. The winning percentage is also 100% and the maximum drawdown is just over 10%. So, is it time to put Merck to work?

Major trade risks: The major trade risk here is that an economic downturn also drags on Merck’s share price and/or some specific news hinders the share price.

Learn more about HYCM

Author

Giles Coghlan LLB, Lth, MA

Financial Source

Giles is the chief market analyst for Financial Source. His goal is to help you find simple, high-conviction fundamental trade opportunities. He has regular media presentations being featured in National and International Press.

British Pound eases to 1.3450 area following downwardly revised Manufacturing PMI data

The British Pound is trimming previous gains against the US Dollar on Monday, returning to the mid-range of the 1.3400s down from fresh seven-week highs, above 1.3500 earlier on the day. Weaker-than-expected UK manufacturing data added pressure on the Pound, which rallied at the Asian session opening, amid news of a halt to the hostilities in Iran.

EUR/USD consolidates previous week's gains above 1.1500

EUR/USD struggles to build on the previous week's impressive gains but manages to hold comfortably above 1.1500 on Monday. The USD loses traction and helps the pair hold its ground following US President Trump's call off an attack on Iran and that talks between the two sides would happen on Monday. Traders will closely monitor the developments surrounding US-Iran negotiations and US ISM PMI data.

Gold extends range play below $4,100 as focus remains on Middle East

Gold struggles to capitalize on its weekly bullish gap and remains below the $4,100 mark in the second half of the day. The US Dollar stages a modest recovery from its lowest level since June 17, which is seen capping the upside for the commodity. The upside for the USD, however, seems limited amid renewed hopes for a US-Iran peace deal and receding US Fed rate-hike expectations.

Week ahead: US payrolls report and AI earnings to keep investors on edge

After the Fed decision, NFP report awaited for more rate hike clues. Employment also on the agenda in Canada and New Zealand. Chinese trade and Japanese wage data to be watched too. But Iran and AI headlines to remain in driver’s seat for risk sentiment.

Solana risks a steeper decline below $70 despite steady ETF inflows

Solana (SOL) is trading in the red, losing bullish momentum and remaining capped below its 50-day Exponential Moving Average at $75.68. SOL-focused Exchange Traded Funds show resilience with a monthly inflow of $14.62 million in July, while the near-term retail support wanes with the funding rate turning negative.

9-3: Is the Federal Reserve’s vote tally Warsh's new forward guidance?

The rate did not move. Neither did the statement, and that’s the more interesting fact. Set the July 29 Federal Open Market Committee (FOMC) statement beside the one issued on June 17, and the two documents are identical apart from a single verb and a paragraph at the bottom naming three dissenters.